

# Ma Ai Thanda Han

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3707590/publications.pdf>

Version: 2024-02-01

17  
papers

461  
citations

1163117  
8  
h-index

1199594  
12  
g-index

17  
all docs

17  
docs citations

17  
times ranked

807  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                      | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1  | MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. Liver International, 2020, 40, 2242-2251.                                                       | 3.9 | 48        |
| 2  | Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. Life, 2020, 10, 198.                                                                                                                                  | 2.4 | 11        |
| 3  | Fibrosis Changes in the Placebo Arm of NASH Clinical Trials. Clinical Gastroenterology and Hepatology, 2019, 17, 2387.                                                                                                       | 4.4 | 3         |
| 4  | The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 764-775.                             | 2.8 | 15        |
| 5  | A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral Research, 2019, 163, 149-155.                                                                | 4.1 | 6         |
| 6  | THU-311-Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study. Journal of Hepatology, 2019, 70, e297.                                                                     | 3.7 | 0         |
| 7  | Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 616-629.e26. | 4.4 | 91        |
| 8  | Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV patients: A phase 2 LOWR HDV-3 study. Journal of Hepatology, 2018, 68, S508.                                                   | 3.7 | 1         |
| 9  | Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). Expert Review of Clinical Pharmacology, 2017, 10, 379-390.                                              | 3.1 | 30        |
| 10 | Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatology Communications, 2017, 1, 288-292.                                                          | 4.3 | 10        |
| 11 | Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. BioMed Research International, 2017, 2017, 1-8.               | 1.9 | 29        |
| 12 | Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients with Chronic Hepatitis Delta Virus Infection. Journal of Hepatology, 2016, 64, S589.                                                                | 3.7 | 0         |
| 13 | Tu1725 Deficiency of Adenosine Deaminase 2 (DADA2); A Rare Cause of Hepatoportal Sclerosis and Non-Cirrhotic Portal Hypertension. Gastroenterology, 2016, 150, S1172-S1173.                                                  | 1.3 | 0         |
| 14 | Hepatobiliary and Pancreatic: Not all that "Glisson's" is fat. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1515-1515.                                                                                  | 2.8 | 0         |
| 15 | LP36 : Understanding hepatitis delta virus and HBsAg kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling. Journal of Hepatology, 2015, 62, S281-S282.                                  | 3.7 | 0         |
| 16 | Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infectious Diseases, The, 2015, 15, 1167-1174.          | 9.1 | 216       |
| 17 | The emperor's new clothes: hypersensitivity of the new cardiac isoenzymes. Journal of Community Hospital Internal Medicine Perspectives, 2013, 3, 20354.                                                                     | 0.8 | 1         |